Xenon Pharmaceuticals Inc. (XENE): Total Liabilities
$51.40M
As of 2025-12-31
$53.38M
As of 2026-06-30
+16.3%
3-year compound annual growth
+23.6%
5-year compound annual growth
+33.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.40M | +18.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $43.24M | +17.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $36.88M | +12.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $32.65M | +48.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $21.97M | +23.2% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $17.83M | -68.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $55.72M | +191.2% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $19.13M | +87.8% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $10.19M | +184.1% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $3.59M | +23.0% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $2.92M | -80.1% | 2017-03-08, Balance as of period end |
| 2014-12-31 | $14.64M | -51.8% | 2016-03-08, Balance as of period end |
| 2013-12-31 | $30.37M | n/a | 2015-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
Compare XENE, ADAG, BOLT, OVID side by side · Screen every company in Pharmaceutical Preparations ↗